These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity. Holgate RG; Weldon R; Jones TD; Baker MP PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145 [TBL] [Abstract][Full Text] [Related]
4. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Ambrose LR; Morel AS; Warrens AN Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623 [TBL] [Abstract][Full Text] [Related]
5. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment. Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943 [TBL] [Abstract][Full Text] [Related]
6. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688 [TBL] [Abstract][Full Text] [Related]
7. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788 [TBL] [Abstract][Full Text] [Related]
8. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. Qi J; Chen SS; Chiorazzi N; Rader C Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356 [TBL] [Abstract][Full Text] [Related]
9. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. von Kutzleben S; Pryce G; Giovannoni G; Baker D Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187 [TBL] [Abstract][Full Text] [Related]
10. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892 [TBL] [Abstract][Full Text] [Related]
11. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019 [TBL] [Abstract][Full Text] [Related]
12. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510 [TBL] [Abstract][Full Text] [Related]
13. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383 [TBL] [Abstract][Full Text] [Related]
14. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Pulaski HL; Spahlinger G; Silva IA; McLean K; Kueck AS; Reynolds RK; Coukos G; Conejo-Garcia JR; Buckanovich RJ J Transl Med; 2009 Jun; 7():49. PubMed ID: 19545375 [TBL] [Abstract][Full Text] [Related]
15. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239 [TBL] [Abstract][Full Text] [Related]
16. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. Focarelli R; Francavilla S; Francavilla F; Della Giovampaola C; Santucci A; Rosati F Mol Hum Reprod; 1999 Jan; 5(1):46-51. PubMed ID: 10050661 [TBL] [Abstract][Full Text] [Related]
17. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652 [TBL] [Abstract][Full Text] [Related]
18. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276 [TBL] [Abstract][Full Text] [Related]
19. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489 [TBL] [Abstract][Full Text] [Related]